Delayed Anthera data release shows increased heart risk

Share this article:

Data released at the American Heart Association meeting in Dallas over Anthera's discontinued Phase III cardiovascular disease drug varespladib has taken researchers by surprise: the company pulled the drug from testing last year, and the data shows that it boosted the risk of heart attack and stroke among patients. The New York Times and FierceBiotech find the data dump has triggered a slew of criticism against the pharmaceutical company for failure to provide this information earlier.

The Cleveland Clinic's Steven Nissen tells the NYT that Anthera “stonewalled every attempt to acquire the data,” and MedScape reports that the study's lead researcher, Stephen Nicholls, has taken a similar stance, telling the publication that Anthera withheld data “despite multiple requests.” The NYT says Nicholls asserts Anthera also failed to provide the agreed-upon, six-month follow-up for the majority of the clinical trial patients, a gap the NYT says makes it hard to confirm the drug increased mortality risk.

Anthera tells Fierce it did not delay publication.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.